Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.48 |
| ▸ | DRD4 | P21917 | 5/20 | 0.48 |
| ▸ | DRD3 | P35462 | 5/20 | 0.48 |
| ▸ | WDR5 | P61964 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL22264983 | 0.93 | KCNH2 (0.46) | LMNADRD2DRD4DRD3WDR5 | |
| SCHEMBL11770355 | 0.86 | NQO1 (0.47) | LMNANQO1TDP1 | |
| SCHEMBL2410855 | 0.80 | DRD2 (0.61) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL5825048 | 0.80 | DRD2 (0.55) | DRD2DRD4DRD3WDR5L3MBTL1 | |
| SCHEMBL1148163 | 0.79 | NQO1 (0.74) | NQO1MAPTTDP1 | |
| SCHEMBL7029327 | 0.79 | CA1 (0.58) | ACHEL3MBTL1NPSR1MAPTTDP1 | |
| SCHEMBL6298426 | 0.78 | DRD2 (0.59) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL1688857 | 0.78 | ACHE (0.52) | DRD2DRD4DRD3WDR5ACHE | |
| SCHEMBL313373 | 0.78 | DRD2 (0.64) | DRD2DRD4DRD3WDR5ACHE | |
| SCHEMBL20530526 | 0.77 | DRD2 (0.57) | DRD2DRD4DRD3L3MBTL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802492-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-11-06 | — | — | EP | disclosed |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-04-30 | — | — | US | disclosed |
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-15 | — | — | US | disclosed |
| EP-3802492-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | Oxford University Innovation Limited (GB) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019234405-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-12-12 | — | — | WO | disclosed |
| CN-106795118-B | Heterocyclic compound and their purposes as relevant orphan receptor (ROR) the GAMMA-T inhibitor of retinoids | 武田药品工业株式会社 | 2019-10-08 | — | — | CN | disclosed |
| CN-109942560-A | MACROCYCLIZATION REACTIONS AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANALOGS OF HALICHONDRIN B | 卫材R&D管理有限公司 | 2019-06-28 | — | — | CN | disclosed |
| CN-105683198-B | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B | 卫材R&D管理有限公司 | 2019-03-12 | — | — | CN | disclosed |
| CN-104470925-B | Imidazo-triazine formonitrile HCN as kinase inhibitor | 百时美施贵宝公司 | 2017-12-05 | — | — | CN | disclosed |
| CN-106795118-A | Heterocyclic compound to they as related orphan receptor (ROR) the GAMMA T inhibitor of retinoids purposes | 武田药品工业株式会社 | 2017-05-31 | — | — | CN | disclosed |
| CN-103209954-A | 4-substituted-3-benzyloxy-bicyclo [3.1.0] hexane compounds as mGluR 2/3 antagonists | LILLY CO ELI | 2013-07-17 | — | — | CN | disclosed |
| CN-102232075-A | Aminopyrazole compounds | LILLY CO ELI | 2011-11-02 | — | — | CN | disclosed |
| CN-1875054-B | Charge-transporting compound, charge-transporting material, charge-transporting varnish, charge-transporting thin film, and organic electroluminescent device | NISSAN CHEMICAL IND LTD | 2011-05-25 | — | — | CN | disclosed |
| US-20100230634-A1 | METHOD FOR PRODUCING BIPHENYL DERIVATIVE | Hayashi, Tamio (JP) | 2010-09-16 | — | — | US | disclosed |
| CN-1875054-A | Charge-transporting compound, charge-transporting material, charge-transporting varnish, charge-transporting thin film, and organic electroluminescent device | NISSAN CHEMICAL IND LTD (JP) | 2006-12-06 | — | — | CN | disclosed |
| US-4835312-A | Production process of N-substituted amide compounds | MITSUI CHEMICALS, INCORPORATED (JP) | 1989-05-30 | — | — | US | disclosed |
| US-4705791-A | ANTICARCINOGENIC AGENTS, IMMUNOLOGY, SKIN DISORDERS | NYEGAARD & CO. A/S (NO) | 1987-11-10 | — | — | US | disclosed |
| US-4596870-A | Substituted pyrimidin-2-ones and the salts thereof | NYEGAARD & CO. A.S. (NO) | 1986-06-24 | — | — | US | disclosed |
| EP-0056319-B1 | SUBSTITUTED PYRIMIDIN-2-ONES AND THE SALTS THEREOF | NYEGAARD & CO. A/S (NO) | 1986-04-16 | — | — | EP | disclosed |
| EP-0056319-A2 | Substituted pyrimidin-2-ones and the salts thereof | NYEGAARD & CO. A/S (NO) | 1982-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214322-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | KRAS, NRAS, HRAS | LMNA 3363/4885DRD2 4780/4885DRD4 4782/4885 |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | KRAS, NRAS, HRAS | LMNA 3363/4885DRD2 4780/4885DRD4 4782/4885 |
| US-20100230634-A1 | METHOD FOR PRODUCING BIPHENYL DERIVATIVE | CYP2E1, DDT, B2M | LMNA 2726/4885DRD2 753/4885DRD4 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.